GlobeImmune Begins Trial With Hepatitis C Candidate

GlobeImmune has started a Phase II trial to evaluate GI-5005 Tarmogen for the treatment of patients with chronic hepatitis C infection.

The drug is being evaluated as a potential therapy in combination with the standard of care, pegylated interferon plus ribavirin.

The randomized, open-label, multi-arm, multicenter trial is evaluating GI-5005 in combination with full duration standard of care versus standard of care alone in patients who are either treatment-naive or unresponsive to previous therapy. 

This study will enroll 120 patients in the U.S., India and Europe, GlobeImmune said.